Core Viewpoint - Agomab Therapeutics NV has announced the pricing of its initial public offering (IPO) of 12,500,000 American Depositary Shares (ADSs) at a price of $16.00 per ADS, aiming to raise gross proceeds of $200 million before expenses [1][2]. Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, particularly targeting chronic fibrotic indications with high unmet medical need [6]. - The company's product candidates aim to target established pathways and utilize validated modalities to enhance efficacy while minimizing systemic toxicities, addressing limitations of previous therapeutic approaches [6]. IPO Details - The ADSs are set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AGMB" on February 6, 2026, with the offering expected to close on February 9, 2026, pending customary closing conditions [2]. - J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are serving as joint book-running managers for the offering [2]. - Agomab has granted underwriters a 30-day option to purchase an additional 1,875,000 ADSs at the IPO price [1]. Regulatory Information - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026, with the offering being made solely by means of a prospectus [3].

Company Overview - SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming treatment for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines [5] - The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to address the lack of ophthalmic innovations that utilize durable treatment options [7] Initial Public Offering (IPO) Details - SpyGlass Pharma announced the pricing of its initial public offering of 9,375,000 shares at a public offering price of $16.00 per share, aiming for aggregate gross proceeds of approximately $150 million [1] - The underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "SGP" on February 6, 2026, with the offering expected to close on February 9, 2026 [1] Underwriters and Regulatory Information - Jefferies, Leerink Partners, Citigroup, and Stifel are acting as joint book-running managers for the offering [2] - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026 [3]

Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from the China Center for Drug Evaluation (CDE), following similar clearance from the U.S. FDA, marking a significant milestone in its clinical development for patients with relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance for APG-3288 enhances Ascentage Pharma's pipeline in hematologic malignancies, complementing existing products like Olverembatinib and Lisaftoclax, which have already been approved in China [5]. Group 2: Mechanism of Action and Innovation - APG-3288 utilizes Ascentage Pharma's proprietary PROTAC technology to induce the degradation of BTK, overcoming resistance associated with conventional BTK inhibitors by blocking the BCR-BTK signaling axis at its source [4]. - The drug is designed to provide a novel therapeutic strategy by inducing rapid and sustained degradation of both wild-type BTK and multiple BTK mutants, addressing the urgent clinical need for new treatment options in B-cell malignancies [3][4]. Group 3: Company Background and Strategy - Ascentage Pharma is a global biopharmaceutical company focused on developing innovative therapies for cancer, with a strong presence in hematologic malignancies and a diverse pipeline of drug candidates [8]. - The company has established partnerships with leading biotechnology and pharmaceutical firms, enhancing its research and development capabilities and expanding its global reach [11].

Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from both the U.S. FDA and the China CDE, marking a significant milestone in its clinical development for treating relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance from the China CDE follows the earlier approval from the U.S. FDA, indicating strong global development capabilities in targeted protein degradation [1][6]. Group 2: Mechanism of Action and Clinical Need - APG-3288 is a highly potent and selective BTK degrader developed using Ascentage Pharma's proprietary PROTAC technology, designed to induce degradation of both wild-type BTK and multiple BTK mutants associated with resistance to existing BTK inhibitors [4]. - There is a significant clinical need for new drugs with novel mechanisms of action due to the limitations of current BTK inhibitors, which often face issues of acquired resistance [3][4]. Group 3: Company Background and Pipeline - Ascentage Pharma has established a strong presence in the field of hematologic malignancies, with a portfolio that includes approved products like Olverembatinib and Lisaftoclax, enhancing its pipeline in this area [5][9]. - The company is focused on developing innovative therapies to address unmet medical needs in cancer, leveraging its robust R&D capabilities and global partnerships with leading biotechnology and pharmaceutical companies [8][11].

Market Overview - U.S. equities faced a challenging day on February 5, 2026, with significant sell-offs in technology stocks and negative job market reports impacting investor sentiment [1] - The S&P 500 fell 1.2% to close at 6,798.40, marking its sixth decline in seven trading days since reaching an all-time high [2] - The Nasdaq Composite dropped 1.6% to 22,540.59, while the Dow Jones Industrial Average decreased by 1.2% to 48,908.72 [2] - Bitcoin prices fell below $64,000, reaching their lowest level since October 2024, further exacerbating the downturn [2] Major Market Movers and Corporate News - Alphabet (GOOGL) saw a decline of 0.8% despite stronger-than-expected sales, as investors were concerned about projected capital expenditures for AI infrastructure, estimated at $175 billion to $185 billion for 2026, nearly double the $91.45 billion spent in 2025 [3] - Qualcomm (QCOM) experienced an 8.5% drop due to a disappointing outlook, citing a tightening global memory shortage affecting the smartphone market [4] - Advanced Micro Devices (AMD) fell sharply by 17.3% on a weak outlook, contributing to the semiconductor sector's struggles [4] - Uber Technologies (UBER) declined by 5.2% after missing earnings expectations, while Amgen (AMGN) surged 8.2% on positive earnings results [5] - Eli Lilly (LLY) jumped 10.3% due to strong sales of its drugs, and McKesson (MCK) soared 16.5% after exceeding profit and revenue expectations [5] - Peloton Interactive (PTON) plummeted 28% after reporting weaker-than-expected results, while Estee Lauder (EL) and Snap (SNAP) retreated by 19% and 12%, respectively [6] Job Market Developments - Amazon (AMZN) announced plans to cut approximately 16,000 corporate roles, while UPS revealed 30,000 job cuts [7] - Dow (DOW) reduced its workforce by 4,500 jobs, with Home Depot (HD) and Nike (NKE) also making cuts [7] Economic Indicators - Initial jobless claims for the week ending January 31 rose to 231,000, exceeding economists' estimates [9] - U.S. employers announced over 108,000 layoffs in January, the highest for that month since 2009, with job openings falling to 6.5 million in December, the lowest since 2020 [9] - The Consumer Price Index rose 2.7% over the year in December, indicating persistent inflation despite potential interest rate cuts by the Federal Reserve [10] Upcoming Market Events - Investors are awaiting the release of January U.S. Non-Farm Payrolls, Unemployment Rate, and Average Hourly Earnings data on February 6, which will provide further insights into the labor market [8]

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant decline in stock price [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between April 1, 2024, and December 16, 2025 [1]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 PALISADE-3 trial of fasedienol, which is intended for treating social anxiety disorder [2]. - Following the announcement that the trial did not show statistically significant improvement, Vistagen's stock price plummeted from $4.36 to $0.86, a decline of over 80% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as a top securities litigation firm in the U.S. for seven consecutive years [4].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. will host a conference call on February 12, 2026, to discuss its financial results and corporate updates for the year ending December 31, 2025 [1]. Group 1: Company Overview - Ultragenyx is a biopharmaceutical company focused on developing and commercializing novel products for serious rare and ultra-rare genetic diseases [3]. - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs [3]. - Ultragenyx's management team has extensive experience in the development and commercialization of therapeutics for rare diseases [4]. Group 2: Strategic Approach - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4].

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has received shareholder approval for its merger with Z Squared Inc., which will result in Z Squared becoming a wholly owned subsidiary of Coeptis [1][2]. Company Overview - Coeptis is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4]. - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [4]. Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [5]. - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [5]. Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6]. Z Squared Overview - Z Squared is a digital infrastructure company focused on securing the Dogecoin and Litecoin networks through institutional-scale mining operations [8]. - Upon merger completion, Z Squared plans to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, positioning itself as the largest publicly traded pure-play Dogecoin miner in the U.S. [8]. Operational Model - Z Squared emphasizes efficiency and risk management, converting mined assets to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused strategy [9]. - The company is led by a team with extensive expertise in cryptocurrency mining operations and infrastructure management [9].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no late ...

Core Insights - Verastem's shares increased nearly 8% following the announcement of preliminary sales figures for Q4 and FY2025 [1][6] - The company reported expected net product revenues of approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025, attributed to the U.S. launch of Avmapki Fakzynja Co-pack after FDA approval in May 2025 [2][6] - Verastem ended 2025 with around $205 million in cash and investments, projecting a cash runway into the first half of 2027 [3][6] Financial Performance - Preliminary net product revenues for Q4 2025 are expected to be approximately $17.5 million, while full-year revenues are projected at $30.9 million [2][6] - The company raised $29.4 million through the exercise of outstanding cash warrants by January 25, 2026 [2] Market Position and Growth - Verastem anticipates that the LGSOC commercial launch and development program will become self-sustaining by the second half of 2026, driven by strong sales growth [3][6] - Over the past year, Verastem's shares have increased by 11.4%, compared to a 32.7% rise in the industry [3] Pipeline Developments - The company is focusing on maximizing value from the Avmapki Fakzynja Co-pack launch while advancing a pipeline targeting RAS/MAPK pathway-driven cancers [7] - Avmapki Fakzynja Co-pack is currently being evaluated in the phase III RAMP 301 study, with top-line data expected in mid-2027 [7] - In Japan, the combination drug is being assessed in the mid-stage RAMP201J study, showing a 38% overall response rate, including 57% in KRAS-mutated patients [8] Future Plans - Verastem plans to select the recommended phase II dose in combination with Erbitux (cetuximab) and initiate expansion studies in colorectal cancer in the first half of 2026 [10] - The company aims to report interim data from the phase I/II study of VS-7375 in the first half of 2026 [9] - Updated data on the RAMP 205 study, evaluating avutometinib plus defactinib, is expected in the second quarter of 2026 [11]